Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Adenovirus | Research

The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study

Authors: Khalid Al Sulaiman, Ohoud Aljuhani, Hisham A. Badreldin, Ghazwa B. Korayem, Abeer A. Alenazi, Ahlam H. Alharbi, Albandari Alghamdi, Alaa Alhubaishi, Ali F. Altebainawi, Mohammad Bosaeed, Rand Alotaibi, Ahad Alawad, Nirvana Alnajjar, Khalid Bin Saleh, Walaa A. Sait, Samiah Alsohimi, Meshari M. Alanizy, Sarah A. Almuqbil, Ibrahim Al Sulaihim, Ramesh Vishwakarma, Mai Alalawi, Fatimah Alhassan, Suliman Alghnam

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Previous studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses.

Methods

A multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death.

Results

A total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS).

Conclusion

Critically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Malekifar P, Pakzad R, Shahbahrami R, Zandi M, Jafarpour A, Rezayat SA, et al. Viral coinfection among COVID-19 patient groups: an update systematic review and meta-analysis. Biomed Res Int. 2021;2021. Malekifar P, Pakzad R, Shahbahrami R, Zandi M, Jafarpour A, Rezayat SA, et al. Viral coinfection among COVID-19 patient groups: an update systematic review and meta-analysis. Biomed Res Int. 2021;2021.
4.
go back to reference Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463–4.CrossRefPubMedPubMedCentral Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463–4.CrossRefPubMedPubMedCentral
7.
go back to reference Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int J Infect Dis. 2020;96:683–7.CrossRefPubMedPubMedCentral Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int J Infect Dis. 2020;96:683–7.CrossRefPubMedPubMedCentral
8.
go back to reference Sreenath K, Batra P, Vinayaraj E V., Bhatia R, SaiKiran K, Singh V, et al. Coinfections with other respiratory pathogens among patients with COVID-19. Microbiol Spectr. 2021;9(1). Sreenath K, Batra P, Vinayaraj E V., Bhatia R, SaiKiran K, Singh V, et al. Coinfections with other respiratory pathogens among patients with COVID-19. Microbiol Spectr. 2021;9(1).
9.
go back to reference Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy. Sci Total Environ. 2020;738. Zoran MA, Savastru RS, Savastru DM, Tautan MN. Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy. Sci Total Environ. 2020;738.
10.
go back to reference Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2(6): 010406. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2(6): 010406.
11.
go back to reference Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):E98-106.CrossRefPubMed Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):E98-106.CrossRefPubMed
12.
go back to reference Silva DL, Lima CM, Magalhães VCR, Baltazar LM, Peres NTA, Caligiorne RB, et al. Fungal and bacterial co-infections increase mortality of severely ill COVID-19 patients. J Hosp Infect. 2021;113:145–54.CrossRefPubMedPubMedCentral Silva DL, Lima CM, Magalhães VCR, Baltazar LM, Peres NTA, Caligiorne RB, et al. Fungal and bacterial co-infections increase mortality of severely ill COVID-19 patients. J Hosp Infect. 2021;113:145–54.CrossRefPubMedPubMedCentral
13.
go back to reference Chekuri S, Szymczak WA, Goldstein DY, Nori P, Marrero Rolon R, Spund B, et al. SARS-CoV-2 co-infection with additional respiratory virus does not predict severe disease: a retrospective cohort study. J Antimicrob Chemother. 2021;76(Supplement_3):III12–9.CrossRefPubMed Chekuri S, Szymczak WA, Goldstein DY, Nori P, Marrero Rolon R, Spund B, et al. SARS-CoV-2 co-infection with additional respiratory virus does not predict severe disease: a retrospective cohort study. J Antimicrob Chemother. 2021;76(Supplement_3):III12–9.CrossRefPubMed
14.
go back to reference Alqahtani A, Alamer E, Mir M, Alasmari A, Alshahrani MM, Asiri M, et al. Bacterial coinfections increase mortality of severely Ill COVID-19 patients in Saudi Arabia. Int J Environ Res Public Health. 2022;19(4). Alqahtani A, Alamer E, Mir M, Alasmari A, Alshahrani MM, Asiri M, et al. Bacterial coinfections increase mortality of severely Ill COVID-19 patients in Saudi Arabia. Int J Environ Res Public Health. 2022;19(4).
16.
go back to reference Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, Lihawa N. Comorbidities and mortality in COVID-19 patients. Gac Sanit. 2021;35(Suppl 2):S530–2.CrossRefPubMedPubMedCentral Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, Lihawa N. Comorbidities and mortality in COVID-19 patients. Gac Sanit. 2021;35(Suppl 2):S530–2.CrossRefPubMedPubMedCentral
18.
go back to reference Echenique IA, Chan PA, Chapin KC, Andrea SB, Fava JL, Mermel LA. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. PLoS ONE. 2013;8(4): e60845.CrossRefPubMedPubMedCentral Echenique IA, Chan PA, Chapin KC, Andrea SB, Fava JL, Mermel LA. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. PLoS ONE. 2013;8(4): e60845.CrossRefPubMedPubMedCentral
19.
go back to reference Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Single, dual and multiple respiratory virus infections and risk of hospitalization and mortality. Epidemiol Infect. 2015;143(1):37–47.CrossRefPubMed Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Single, dual and multiple respiratory virus infections and risk of hospitalization and mortality. Epidemiol Infect. 2015;143(1):37–47.CrossRefPubMed
20.
go back to reference John KJ, Nayar J, Mishra AK, Selvaraj V, Khan MS, Lal A. In-hospital clinical complications of COVID-19: a brief overview. Future Virol. 2021;16(11):717–23.CrossRef John KJ, Nayar J, Mishra AK, Selvaraj V, Khan MS, Lal A. In-hospital clinical complications of COVID-19: a brief overview. Future Virol. 2021;16(11):717–23.CrossRef
21.
go back to reference Farias LdPGd, Strabelli DG, Fonseca EKUN, Loureiro BMC, Nomura CH, Sawamura MVY. Thoracic tomographic manifestations in symptomatic respiratory patients with COVID-19. Radiol Bras. 2020;53(4):255.CrossRefPubMedPubMedCentral Farias LdPGd, Strabelli DG, Fonseca EKUN, Loureiro BMC, Nomura CH, Sawamura MVY. Thoracic tomographic manifestations in symptomatic respiratory patients with COVID-19. Radiol Bras. 2020;53(4):255.CrossRefPubMedPubMedCentral
22.
go back to reference Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, et al. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Front Med. 2021;25(8):971. Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, et al. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Front Med. 2021;25(8):971.
23.
go back to reference Al Sulaiman K, Korayem GB, Altebainawi AF, Al Harbi S, Alissa A, Alharthi A, et al. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study. Crit Care. 2022;26(1):304.CrossRefPubMedPubMedCentral Al Sulaiman K, Korayem GB, Altebainawi AF, Al Harbi S, Alissa A, Alharthi A, et al. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study. Crit Care. 2022;26(1):304.CrossRefPubMedPubMedCentral
Metadata
Title
The clinical outcomes of COVID-19 critically ill patients co-infected with other respiratory viruses: a multicenter, cohort study
Authors
Khalid Al Sulaiman
Ohoud Aljuhani
Hisham A. Badreldin
Ghazwa B. Korayem
Abeer A. Alenazi
Ahlam H. Alharbi
Albandari Alghamdi
Alaa Alhubaishi
Ali F. Altebainawi
Mohammad Bosaeed
Rand Alotaibi
Ahad Alawad
Nirvana Alnajjar
Khalid Bin Saleh
Walaa A. Sait
Samiah Alsohimi
Meshari M. Alanizy
Sarah A. Almuqbil
Ibrahim Al Sulaihim
Ramesh Vishwakarma
Mai Alalawi
Fatimah Alhassan
Suliman Alghnam
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08010-8

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine